Journal ArticleDOI
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Caroline J. Breitbach,James M. Burke,Derek J. Jonker,Derek J. Jonker,Joe Stephenson,Andrew R. Haas,Laura Q M Chow,Laura Q M Chow,Jorge Nieva,Tae-Ho Hwang,Anne Moon,Richard H. Patt,Adina Pelusio,Fabrice Le Boeuf,Joseph K. Burns,Joseph K. Burns,Laura Evgin,Laura Evgin,Naomi De Silva,Naomi De Silva,Sara Cvancic,Sara Cvancic,Terri Robertson,Ji Eun Je,Yeon Sook Lee,Kelley Parato,Jean-Simon Diallo,Aaron Fenster,Manijeh Daneshmand,Manijeh Daneshmand,John C. Bell,John C. Bell,David H. Kirn +32 more
TLDR
It is shown in a clinical trial that JX-594 selectively infects, replicates and expresses transgene products in cancer tissue after intravenous infusion, in a dose-related fashion.Abstract:
Oncolytic viruses, either natural or engineered, preferentially infect and lyse tumour cells. David Kirn and colleagues now report a phase I clinical trial in which they demonstrate systemic delivery of the engineered oncolytic virus JX-594 selectively to tumour tissue after a single injection. Tumour biopsies indicate that the virus replicates in cancer but not in adjacent normal tissue. JX-594 is engineered to replicate in a broad spectrum of cancer cells harbouring activation of the epidermal growth factor receptor/Ras pathway. Although the trial was not designed to demonstrate clinical efficacy, the results suggest that JX-594 may elicit a clinical response in some patients. The efficacy and safety of biological molecules in cancer therapy, such as peptides and small interfering RNAs (siRNAs), could be markedly increased if high concentrations could be achieved and amplified selectively in tumour tissues versus normal tissues after intravenous administration. This has not been achievable so far in humans. We hypothesized that a poxvirus, which evolved for blood-borne systemic spread in mammals, could be engineered for cancer-selective replication and used as a vehicle for the intravenous delivery and expression of transgenes in tumours. JX-594 is an oncolytic poxvirus engineered for replication, transgene expression and amplification in cancer cells harbouring activation of the epidermal growth factor receptor (EGFR)/Ras pathway, followed by cell lysis and anticancer immunity1. Here we show in a clinical trial that JX-594 selectively infects, replicates and expresses transgene products in cancer tissue after intravenous infusion, in a dose-related fashion. Normal tissues were not affected clinically. This platform technology opens up the possibility of multifunctional products that selectively express high concentrations of several complementary therapeutic and imaging molecules in metastatic solid tumours in humans.read more
Citations
More filters
Journal ArticleDOI
Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications.
TL;DR: In this review, state-of-the-art nanoparticles and targeted systems that have been investigated in clinical studies are discussed and the challenges faced in using nanomedicine products and translating them from a preclinical level to the clinical setting are emphasized.
Journal ArticleDOI
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo,Tony R. Reid,Leyo Ruo,Caroline J. Breitbach,Steven C. Rose,Mark Bloomston,Mong Cho,Ho Yeong Lim,Hyun Cheol Chung,Chang Won Kim,James M. Burke,Riccardo Lencioni,Theresa Hickman,Anne Moon,Yeon Sook Lee,Mi Kyeong Kim,Manijeh Daneshmand,Kara S DuBois,Lara Longpre,Minhtran C. Ngo,Cliona M. Rooney,John C. Bell,Byung Geon Rhee,Richard H. Patt,Tae-Ho Hwang,David H. Kirn +25 more
TL;DR: JX-594 demonstrated oncolytic and immunotherapy MOA, tumor responses and dose-related survival in individuals with HCC, and subject survival duration was significantly related to dose.
Journal ArticleDOI
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin,Dmitriy Zamarin,Rikke B. Holmgaard,Rikke B. Holmgaard,Sumit K. Subudhi,Joon Seok Park,Joon Seok Park,Mena Mansour,Peter Palese,Taha Merghoub,Taha Merghoub,Jedd D. Wolchok,James P. Allison +12 more
TL;DR: In this article, the authors explored the immunotherapeutic potential of oncolytic Newcastle disease virus (NDV) and found that localized intratumoral therapy of B16 melanoma with NDV induces inflammatory responses, leading to lymphocytic infiltrates and antitumor effect in distant (nonvirally injected) tumors without distant virus spread.
Journal ArticleDOI
Oncolytic virus therapy: A new era of cancer treatment at dawn
TL;DR: It appears that it will not be long before oncolytic virus therapy becomes a standard therapeutic option for all cancer patients, following the success in immunotherapy using immune checkpoint inhibitors.
Journal ArticleDOI
Going viral with cancer immunotherapy
TL;DR: The ability to engineer OVs that express immune-stimulating 'cargo', the induction of immunogenic tumour cell death by OVs and the selective targeting of OVs to tumour beds suggests that they are the ideal reagents to enhance antitumour immune responses.
References
More filters
Journal ArticleDOI
The hallmarks of cancer.
TL;DR: This work has been supported by the Department of the Army and the National Institutes of Health, and the author acknowledges the support and encouragement of the National Cancer Institute.
Book ChapterDOI
Primer3 on the WWW for general users and for biologist programmers.
Steve Rozen,Helen Skaletsky +1 more
TL;DR: This chapter assumes acquaintance with the principles and practice of PCR, as outlined in, for example, refs.
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis,Jonathan E. Zuckerman,Chung Hang Jonathan Choi,David Seligson,Anthony W. Tolcher,Christopher A. Alabi,Christopher A. Alabi,Yun Yen,Jeremy D. Heidel,Antoni Ribas +9 more
TL;DR: Evidence is provided of inducing an RNAi mechanism of action in a human from the delivered siRNA and the presence of an mRNA fragment that demonstrates that siRNA-mediated mRNA cleavage occurs specifically at the site predicted for anRNAi mechanism from a patient who received the highest dose of the nanoparticles.
Journal ArticleDOI
Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria
Haesun Choi,Chuslip Charnsangavej,Silvana de Castro Faria,Homer A. Macapinlac,Michael A. Burgess,Shreyaskumar Patel,Lei L. Chen,Donald A. Podoloff,Robert S. Benjamin +8 more
TL;DR: Small changes in tumor size or density on CT are sensitive and specific methods of assessing the response of GISTs, and the prognostic value of the proposed CT response criteria should be employed in future studies of patients with GIST.
Related Papers (5)
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo,Tony R. Reid,Leyo Ruo,Caroline J. Breitbach,Steven C. Rose,Mark Bloomston,Mong Cho,Ho Yeong Lim,Hyun Cheol Chung,Chang Won Kim,James M. Burke,Riccardo Lencioni,Theresa Hickman,Anne Moon,Yeon Sook Lee,Mi Kyeong Kim,Manijeh Daneshmand,Kara S DuBois,Lara Longpre,Minhtran C. Ngo,Cliona M. Rooney,John C. Bell,Byung Geon Rhee,Richard H. Patt,Tae-Ho Hwang,David H. Kirn +25 more
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H.I. Andtbacka,Howard L. Kaufman,Frances A. Collichio,Thomas Amatruda,Neil Senzer,Jason Chesney,Keith A. Delman,Lynn E. Spitler,Igor Puzanov,Sanjiv S. Agarwala,Mohammed M. Milhem,Lee D. Cranmer,Brendan D. Curti,Karl D. Lewis,Merrick I. Ross,Troy H. Guthrie,Gerald P. Linette,Gregory A. Daniels,Kevin J. Harrington,Mark R. Middleton,Wilson H. Miller,Jonathan S. Zager,Yining Ye,Bin Yao,Ai Li,Susan Doleman,Ari M. Vanderwalde,Jennifer Gansert,Robert Coffin +28 more